CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.62M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.94: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
275.09MGBP364.98M · vs all stocks (USD)
Revenue (TTM)
3.48MGBP4.62M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7780xvs all stocks
52-Week Change
-8.83%vs all stocks
Market Capitalization
275.09MGBP364.98M · vs all stocks (USD)
Enterprise Value
151.38MGBP200.84M · vs all stocks (USD)
Forward P/E
-4.57xvs Biotechnology peers
Price to Sales (TTM)
63.68xvs Biotechnology peers
Price to Book (MRQ)
1.26xvs Biotechnology peers
Enterprise to Revenue
43.50xvs Biotechnology peers
Enterprise to EBITDA
-2.09xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1797.79%vs Biotechnology peers
Return on Assets (TTM)
-10.82%vs Biotechnology peers
Return on Equity (TTM)
-30.85%vs Biotechnology peers
Revenue (TTM)
3.48MGBP4.62M · vs all stocks (USD)
Revenue per Share (TTM)
0.0190GBPUpdated Sep 23, 2026Quarterly Revenue Growth
-38.20%vs Biotechnology peers
Gross Profit (TTM)
-38.69MGBP-51.33M · vs all stocks (USD)
EBITDA (TTM)
-72.32MGBP-95.95M · vs all stocks (USD)
Net Income (TTM)
-81.96MGBP-108.74M · vs all stocks (USD)
Operating Cash Flow (TTM)
-63.58MGBP-84.36M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-67.21MGBP-89.17M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-6.40MUSDFY2025 · Dec 31, 2025Revenue
4.66MUSDFY2025 · Dec 31, 2025Operating Income
-98.53MUSDvs all stocks (USD)
Pre-tax Income
-110.93MUSDFY2025 · Dec 31, 2025Income Tax Expense
-842.00KUSDFY2025 · Dec 31, 2025Net Income
-110.08MUSDFY2025 · Dec 31, 2025EBIT
-65.15MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-102.36MUSDFY2025 · Dec 31, 2025Research & Development
45.74MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
20.65MUSDFY2025 · Dec 31, 2025Other Operating Expenses
1.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.05MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
240.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
240.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-110.08MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
345.00KUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-69.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
-69.63MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
252.47MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-110.08MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.22MUSDFY2025 · Dec 31, 2025Other Non-cash Items
32.73MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-236.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
263.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
-888.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-84.20MUSDFY2025 · Dec 31, 2025Sale of Investments
148.06MUSDFY2025 · Dec 31, 2025Other Investing Activity
49.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
63.29MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-2.05MUSDFY2025 · Dec 31, 2025Other Financing Charges
-802.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.75MUSDFY2025 · Dec 31, 2025Shares Outstanding
241.68MSharesUpdated Sep 23, 2026Float Shares
157.42MSharesUpdated Sep 23, 2026% Held by Insiders
10.05%vs all stocks
% Held by Institutions
53.21%vs all stocks
Total Cash (MRQ)
215.64MGBP286.10M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.19GBPUpdated Sep 23, 2026Total Debt (MRQ)
151.81MGBP201.41M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6649xvs Biotechnology peers
Current Ratio (MRQ)
6.59xvs Biotechnology peers
Book Value per Share (MRQ)
0.9639GBPUpdated Sep 23, 2026Total Assets
534.71MUSDvs all stocks (USD)
Total Current Assets
305.02MUSDFY2025 · Dec 31, 2025Total Liabilities
229.03MUSDFY2025 · Dec 31, 2025Total Non-current Assets
229.69MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
182.72MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
252.47MUSDFY2025 · Dec 31, 2025Other Short-term Investments
24.83MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.76MUSDFY2025 · Dec 31, 2025Accounts Payable
3.07MUSDFY2025 · Dec 31, 2025Short-term Debt
8.50MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.42MUSDFY2025 · Dec 31, 2025Long-term Debt
11.09MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
170.42MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.86MUSDFY2025 · Dec 31, 2025Retained Earnings
-77.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.68MUSDvs all stocks (USD)
Treasury Stock
41.15MUSDFY2025 · Dec 31, 202552-Week Low
107.40GBXUpdated Sep 23, 202652-Week High
143.60GBXUpdated Sep 23, 202652-Week Change
-8.83%vs all stocks
Beta
0.7780xvs all stocks
50-Day MA
121.07GBXUpdated Sep 23, 2026200-Day MA
125.49GBXUpdated Sep 23, 2026Avg 10-Day Volume
479.91KSharesUpdated Sep 23, 2026Avg 30-Day Volume
699.94KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
-0.3400GBPUpdated Sep 23, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.59Altman Z-Score: 0.94
Financial Health
Altman Z-Score 0.94: distress zoneCritical
Altman Z-Score: 0.94
Low earnings qualitySignificant
Earnings Quality Score: -0.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.62M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,616,709.223Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk